FluidForm Bio
FluidForm Bio™ is a biotechnology company founded in 2018 and headquartered in Waltham, MA, specializing in 3D bioprinting of living human tissue using its patented FRESH™ technology. This revolutionary platform builds complex, vascularized tissues from cells and proteins, designed to promote dense vascularization and long-term survival of therapeutic cells, enabling minimally invasive, implantable tissue therapies. The company integrates innovations in 3D printing, synthetic biology, AI, and materials science to develop human tissue indistinguishable from natural tissue, targeting treatments for diseases such as type 1 diabetes. FluidForm Bio collaborates with top life science companies and has a leadership team with deep expertise in life sciences, technology, and biomedical engineering. The company has demonstrated significant advancements in engineered heart tissues and vascularized tissue engineering, holds over 20 US patents, and has published landmark research in leading journals, positioning it as a leader in regenerative medicine and biomanufacturing.
FluidForm Bio
FluidForm Bio™ is a biotechnology company founded in 2018 and headquartered in Waltham, MA, specializing in 3D bioprinting of living human tissue using its patented FRESH™ technology. This revolutionary platform builds complex, vascularized tissues from cells and proteins, designed to promote dense vascularization and long-term survival of therapeutic cells, enabling minimally invasive, implantable tissue therapies. The company integrates innovations in 3D printing, synthetic biology, AI, and materials science to develop human tissue indistinguishable from natural tissue, targeting treatments for diseases such as type 1 diabetes. FluidForm Bio collaborates with top life science companies and has a leadership team with deep expertise in life sciences, technology, and biomedical engineering. The company has demonstrated significant advancements in engineered heart tissues and vascularized tissue engineering, holds over 20 US patents, and has published landmark research in leading journals, positioning it as a leader in regenerative medicine and biomanufacturing.